胞苷脱氨酶
癌症研究
吉西他滨
细胞生长
细胞周期
乳腺癌
生物
癌症
细胞周期蛋白D1
癌变
活化诱导(胞苷)脱氨酶
小RNA
免疫学
基因
体细胞突变
遗传学
B细胞
抗体
作者
Fu Gui Ye,Chuan Song,Zhi Cao,Xia Chen,Dan Na Chen,Li Chen,Shan Li,Feng Qiao,Hong Ling,Ling Yao,Xin Hu,Zhi Ming Shao
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2015-03-31
卷期号:75 (7): 1504-1515
被引量:70
标识
DOI:10.1158/0008-5472.can-14-2341
摘要
Abstract There has been little study of how the evolution of chemoresistance in cancer affects other aspects of disease pathogenesis. Here, we show that an important chemoresistance axis driven by cytidine deaminase (CDA) also acts to suppress cell-cycle progression by regulating cyclin E–CDK2 signaling. We found that CDA was regulated by miR-484 in a gemcitabine-resistant model of breast cancer. Elevating miR-484 expression reversed the CDA effects, thereby enhancing gemcitabine sensitivity, accelerating cell proliferation, and redistributing cell-cycle progression. Conversely, elevating CDA to restore its expression counteracted the chemosensitization and cell proliferative effects of miR-484. In clinical specimens of breast cancer, CDA expression was frequently downregulated and inversely correlated with miR-484 expression. Moreover, high expression of CDA was associated with prolonged disease-free survival in studied cohorts. Collectively, our findings established that miR-484–modulated CDA has a dual impact in promoting chemoresistance and suppressing cell proliferation in breast cancer, illustrating the pathogenic tradeoffs associated with the evolution of chemoresistance in this malignant disease. Cancer Res; 75(7); 1504–15. ©2015 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI